Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
NVNuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc. (NVCT)

NASDAQ Capital Market · Currency in USD
$20.05 ▼ -0.84 (-4.02%)
At close: Oct 23, 4:00 PM ET. Market closed.
$20.05 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:04 PM ET

Summary

Previous Close
$20.89
Open
$20.87
Day's Range
$19.83 – $20.87
52 Week Range
$5.55 – $29.28
Volume
107,946
Avg. Volume
284,699
Market Cap
$654.51M
Beta (5Y Monthly)
-0.24
PE Ratio (TTM)
--
EPS (TTM)
-$1.19
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$37.33

Profile: Nuvectis Pharma, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
16
CEO
Ron Bentsur

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.22
DateEst.Actual
Aug 4, 2026-$0.26-$0.30Miss
May 5, 2026-$0.30-$0.26Beat
Feb 11, 2026-$0.26-$0.31Miss
Nov 4, 2025-$0.24-$0.44Miss
Aug 5, 2025-$0.25-$0.30Miss
May 6, 2025-$0.30-$0.27Beat

Analyst view

Consensus price target
$37.33 ▲ +86.2%
Range $33.00 – $40.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on NVCT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.